Pulished Date October, 2018
ID: 162
Share on
Share on

Middle-East and Africa Cancer Monoclonal Antibodies Market by application (Liver, Breast, Blood, Brain, Hodgkin’s and Non-Hodgkin’s lymphoma, Colorectal, leukaemia and others) by type (murine antibodies, chimeric and humanised antibodies and fully humanized antibodies) by Conjugated Cancer therapies and by region - Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts (2018-2023)

Pulished: October, 2018
ID: 162
Pages: 145

Cancer is the leading cause of death across the globe currently. It starts from a single cell in the body genetically transforming a normal cell to a tumour and is eventually spread to other cells. Typically, drugs and chemotherapy are used as a treatment to cure cancer. The adverse side effects that comes with them has made the pharmaceutical companies to concentrate on monoclonal antibodies.

Middle-East & Africa Monoclonal Antibodies Market is estimated to be USD 3 Billion in 2018 and is expected to reach USD 5.11 Billion by 2023 with a growth rate of 11.272%.

Recent years have seen the emergence of monoclonal antibodies owing to its potentiality to offer less toxic and highly efficient alternatives to the patients. The antibodies has the ability to treat many diseases related to inflammatory, autoimmune and especially cancer. The antibodies comprises of identical cells which are clones of a single parent cells and directed towards specific targets cells. Thus monoclonal antibodies due to its specificity to target only cancer cell leaving behind the healthy one, can be a more efficient way of treating cancer than chemotherapies or drugs.

The drastic increase in the people affected by cancer prompted many pharmaceutical firms to invest in monoclonal antibodies. Rise in investment in R&D of genomic studies, technological innovations in target gene selection and genetic sequencing, monoclonal antibodies ability to target only specific cells, having no side effects compared to its counter parts are the primary drivers for the market. With the increased occurrence of cancer, the market is expected to grow significantly in the next 5 years having a presence of highly strong products in the pipeline. There are also few restraints for its market entry like high cost, stringent guidelines, long durations required for R&D, clinical trials.

The segmentation of the Middle-East & Africa on the basis of application is categorised as Leukaemia, Colorectal, Liver, Brain, Breast, Blood, Hodgkins & Non-Hodgkins lymphoma and others. The segmentation based on type is divided as murine antibodies, fully humanised antibodies and chimeric & humanised antibodies. By Conjugated Cancer Therapies it is segmented as Radioimmunotherapy, Immunoliposome, ADEPT, Immunocytokines and others. Based on the geography of Middle-East & Africa it is analysed in UAE, Saudi Arabia, Israel and others.

The highly customizable nature of the monoclonal antibodies are attracting various organizations, research institutes and multinational companies to use it as a tool to cure cancer. The major players in the Cancer Monoclonal Antibodies Market are Amgen, Genmab, glaxosmithkline, Bristol Myers Squibb, Roche, Eli Lilly, Immunogen, Novartis, Seattle Genetics and Spectrum Pharmaceuticals.

 

  1. Introduction

                1.1 Market Definition                                                                    

                1.2 Study Deliverables                                                                  

                1.3 Base Currency, Base Year and Forecast Periods                                                                          

                1.4 General Study Assumptions                                                                

  1. Research Methodology

                2.1 Introduction                                                                               

                2.2 Research Phases                                                                      

                                2.2.1 Secondary Research                                                           

                                2.2.2 Primary Research                                                 

                                2.2.3 Econometric Modelling                                                      

                                2.2.4 Expert Validation                                                  

                2.3 Analysis Design                                                                         

                2.4 Study Timeline                                                                          

  1. Overview

                3.1 Executive Summary                                                                

                3.2 Key Inferences                                                                         

                3.3 New Developments                                                                               

  1. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

                4.1 Market Drivers                                                                          

                4.2 Market Restraints                                                                    

                4.3 Key Challenges                                                                         

                4.4 Current Opportunities in the Market                                                                              

  1. Market Segmentation

                5.1 By Application                                                                           

                                5.1.1 Liver                                                           

                                5.1.2 Breast                                                       

                                5.1.3 Brain                                                          

                                5.1.4 Blood                                                         

                                5.1.5 Hodgkins and Non-Hodgkins lymphoma                                                    

                                5.1.6 Colorectal                                                

                                5.1.7 Leukaemia                                                              

                                5.1.8 Others                                                      

                5.2 By Type                                                                        

                                5.2.1 Murine Antibodies                                                              

                                5.2.2 Chimeric and Humanised Antibodies                                                           

                                5.2.3 Fully Humanized Antibodies                                                            

                5.3 Conjugate Cancer Therapies                                                                               

                                5.3.1 Immunoliposome                                                

                                5.3.2 Radioimmunotherapy                                                        

                                5.3.3 ADEPT                                                       

                                5.3.4 Immunocytokines                                                

                                5.3.5 Others                                                      

  1. Geographical Analysis

                6.1 Introduction                                                                               

                6.2 UAE                                                                               

                6.3Saudi Arabia                                                                

                6.4 Israel                                                                             

                6.5 Others                                                                          

  1. Strategic Analysis

                7.1 PESTLE analysis                                                                         

                                7.1.1 Political                                                     

                                7.1.2 Economic                                                 

                                7.1.3 Social                                                         

                                7.1.4 Technological                                                         

                                7.1.5 Legal                                                          

                                7.1.6 Environmental                                                       

                7.2 Porter’s Five analysis                                                                              

                                7.2.1 Bargaining Power of Suppliers                                                        

                                7.2.2 Bargaining Power of Consumers                                                    

                                7.2.3 Threat of New Entrants                                                     

                                7.2.4 Threat of Substitute Products and Services                                                              

                                7.2.5 Competitive Rivalry within the Industry                                                     

  1. Market Leaders' Analysis

                8.1 Roche                                                           

                                8.1.1 Overview                                                 

                                8.1.2 Product Analysis                                                   

                                8.1.3 Strategic Evaluation and Operations                                                            

                                8.1.4 Financial analysis                                                  

                                8.1.5 Legal issues                                                             

                                8.1.6 Recent Developments                                                       

                                8.1.7 SWOT analysis                                                       

                                8.1.8 Analyst View                                                          

                8.2 Amgen                                                         

                8.3 Genmab                                                      

                8.4 Glaxosmithkline                                                       

                8.5 Bristol Meyer Squibb                                                              

                8.6 Eli Lilly                                                           

                8.7 Immunogen                                                               

                8.8 Novartis                                                       

                8.9 Seattle Genetics                                                       

                8.10 Spectrum Pharmaceuticals                                                

  1. Competitive Landscape

                9.1 Market share analysis                                                                            

                9.2 Merger and Acquisition Analysis                                                                       

                9.3 Agreements, collaborations and Joint Ventures                                                                         

                9.4 New Product Launches                                                                         

  1. Expert Opinions

                10.1 Market Outlook                                                                     

                10.2 Investment Opportunities                                                                 

     Appendix                                                                                           

  1. List of Tables
  2. List of Figures
  • Regional, and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Middle East & Africa Cancer Monoclonal Antibodies Market By Region, From 2018-2023 ( USD Million )
  2. Middle East & Africa Cancer Monoclonal Antibodies Market By Application, From 2018-2023 ( USD Million )
  3. Middle East & Africa Liver Market By Region, From 2018-2023 ( USD Million )
  4. Middle East & Africa Breast Market By Region, From 2018-2023 ( USD Million )
  5. Middle East & Africa Brain Market By Region, From 2018-2023 ( USD Million )
  6. Middle East & Africa Blood Market By Region, From 2018-2023 ( USD Million )
  7. Middle East & Africa Hodgkins and Non-Hodgkins lymphoma Market By Region, From 2018-2023 ( USD Million )
  8. Middle East & Africa Colorectal Market By Region, From 2018-2023 ( USD Million )
  9. Middle East & Africa Leukaemia Market By Region, From 2018-2023 ( USD Million )
  10. Middle East & Africa Others Market By Region, From 2018-2023 ( USD Million )
  11. Middle East & Africa Cancer Monoclonal Antibodies Market By Type, From 2018-2023 ( USD Million )
  12. Middle East & Africa Murine Antibodies Market By Region, From 2018-2023 ( USD Million )
  13. Middle East & Africa Chimeric and Humanised Antibodies Market By Region, From 2018-2023 ( USD Million )
  14. Middle East & Africa Fully Humanized Antibodies Market By Region, From 2018-2023 ( USD Million )
  15. Middle East & Africa Cancer Monoclonal Antibodies Market By Conjugate Cancer Therapies, From 2018-2023 ( USD Million )
  16. Middle East & Africa Immunoliposome Market By Region, From 2018-2023 ( USD Million )
  17. Middle East & Africa Radioimmunotherapy Market By Region, From 2018-2023 ( USD Million )
  18. Middle East & Africa ADEPT Market By Region, From 2018-2023 ( USD Million )
  19. Middle East & Africa Immunocytokines Market By Region, From 2018-2023 ( USD Million )
  20. Middle East & Africa Others Market By Region, From 2018-2023 ( USD Million )
  21. UAE Cancer Monoclonal Antibodies Market By Application, From 2018-2023 ( USD Million )
  22. UAE Cancer Monoclonal Antibodies Market By Type, From 2018-2023 ( USD Million )
  23. UAE Cancer Monoclonal Antibodies Market By Conjugate Cancer Therapies, From 2018-2023 ( USD Million )
  24. Saudi Arabia Cancer Monoclonal Antibodies Market By Application, From 2018-2023 ( USD Million )
  25. Saudi Arabia Cancer Monoclonal Antibodies Market By Type, From 2018-2023 ( USD Million )
  26. Saudi Arabia Cancer Monoclonal Antibodies Market By Conjugate Cancer Therapies, From 2018-2023 ( USD Million )
  27. Israel Cancer Monoclonal Antibodies Market By Application, From 2018-2023 ( USD Million )
  28. Israel Cancer Monoclonal Antibodies Market By Type, From 2018-2023 ( USD Million )
  29. Israel Cancer Monoclonal Antibodies Market By Conjugate Cancer Therapies, From 2018-2023 ( USD Million )

LICENCE TYPE

$ 1234 2875

Clients
clients
clients
clients
clients
clients
clients